### Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 4

KERYX BIOPHARMACEUTICALS INC Form 4 March 10, 2006 OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person \* 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading **KESSEL LARRY** Issuer Symbol **KERYX** (Check all applicable) **BIOPHARMACEUTICALS INC** [KERX] X\_ Director 10% Owner Officer (give title Other (specify (Last) (First) (Middle) 3. Date of Earliest Transaction below) below) (Month/Day/Year) C/O KERYX 03/08/2006 **BIOPHARMACEUTICALS**, INC., 750 LEXINGTON AVE. (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) \_X\_ Form filed by One Reporting Person Form filed by More than One Reporting NEW YORK, NY 10022 Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired 5. Amount of 6. Ownership 7. Nature of Transaction(A) or Disposed of (D) Form: Direct Indirect Security (Month/Day/Year) Execution Date, if Securities (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially (D) or Beneficial anv (Month/Day/Year) (Instr. 8) Owned Indirect (I) Ownership Following (Instr. 4) (Instr. 4) Reported (A) Transaction(s) or (Instr. 3 and 4) Price Code V Amount (D) Common S 03/08/2006 85.926 D M 75,000 Α 1 92 Stock Common 03/08/2006 S 75.000 D 10.926 D 17.2Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

## Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 4

#### number.

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount o Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Options (Right to Buy)	\$ 1.92	03/08/2006		М	25,000	06/23/2003 <u>(1)</u>	06/23/2013	Common Stock	25,000
Options (Right to Buy)	\$ 1.92	03/08/2006		М	50,000	06/23/2004 <u>(2)</u>	06/23/2013	Common Stock	50,000

# **Reporting Owners**

Reporting Owner Name / Addr	Relationships				
reporting o when runne / runness		Director	10% Owner	Officer	Other
KESSEL LARRY C/O KERYX BIOPHARMACEUTIC 750 LEXINGTON AVE. NEW YORK, NY 10022	CALS, INC.	X			
Signatures					
/s/ Ron Bentsur, Attorney in fact	03/10/2006				
<u>**</u> Signature of Reporting Person	Date				

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). \*\*
- 5,000 options vested on 6/23/03, and an additional 5,000 options vested on each of the following dates: 9/23/03, 12/23/03, 3/23/04, and (1) 6/23/04.
- (2) 25,000 options vested on 6/23/04, and an additional 25,000 options vested on 6/23/05.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.